Browsing Tag
faridoxorubicin
7 posts
Avacta (AIM: AVCT): First patient dosed in FOCUS-01 with three data catalysts lined up across 2026
Avacta (AIM: AVCT) dosed the first FOCUS-01 patient in March 2026. Three catalysts follow: AACR April 21, AVA6000 H1 update, AVA6103 late H2 data. Full retail investor roadmap inside.
Avacta (AVCT) at AACR 2026: What the San Diego data presentations actually mean if you’re holding shares through the trial
Avacta Therapeutics (AIM: AVCT) is presenting two posters at AACR 2026 in San Diego. Here is what investors need to understand about conference data versus clinical trial readouts and which milestones actually move the stock.
Avacta (AIM: AVCT) investor roadmap: The milestones that matter between now and the AVA6103 data readout in late 2026
Avacta (AVCT) faces two clinical data readouts in 2026. This investor roadmap maps every milestone, risk, and signal to watch through the AVA6103 Phase 1 readout.
Avacta Group (AIM: AVCT) closes oversubscribed £10m placing at 9.35% discount as AVA6103 enters clinical dosing
Avacta Group (AIM: AVCT) completes an oversubscribed £10m equity placing at 63p ahead of late-2026 AVA6103 Phase 1 data. Read the full analyst breakdown.
Avacta Therapeutics (AIM: AVCT) reports 90% disease control rate in faridoxorubicin salivary gland cancer trial
Avacta Therapeutics’ AVA6000 trial shows a 90% disease control rate in salivary gland cancer. Find out how its tumor-activated approach could reshape chemotherapy.
Is Avacta Therapeutics changing the rules of chemotherapy? Inside the Phase 1a findings that impressed ESMO
Avacta Therapeutics’ Phase 1a trial data shows faridoxorubicin’s tumor-targeted action and cardiac safety. Explore the implications for pre|CISION in solid tumors.
Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate?
Avacta raises £16m to extend clinical runway into 2026 and reports 91% disease control in cancer trial. See why investors are watching AVCT closely.